Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Konstantinos Vardakas
Journal of Antimicrobial Chemotherapy, 2012
View PDFchevron_right
Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort
Nuria Prim
Clinical Infectious Diseases, 2017
View PDFchevron_right
Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study.
Constantinos Tsioutis
J Antimicrob Chemother, 2011
View PDFchevron_right
Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials
Cathy Emmas
European Journal of Clinical Microbiology & Infectious Diseases, 2008
View PDFchevron_right
Antibiotic use and the risk of carbapenem-resistant extended-spectrum-β-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case–control study
Constantinos Tsioutis
Journal of Antimicrobial Chemotherapy, 2011
View PDFchevron_right
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
angela chow
PloS one, 2016
View PDFchevron_right
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum- -Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Prior use of carbapenems may be a significant risk factor for extended-spectrum -lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia
Frederick Lopez
Journal of Antimicrobial Chemotherapy, 2006
View PDFchevron_right
Antibiotic use and the risk of carbapenem-resistant extended-spectrum- -lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study
Achilleas Gikas
Journal of Antimicrobial Chemotherapy, 2011
View PDFchevron_right
Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
Jaminah Ali
Antimicrobial Resistance and Infection Control, 2015
View PDFchevron_right
Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review
Niels Frimodt-møller
Acta Anaesthesiologica Scandinavica, 2019
View PDFchevron_right
Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study
Sonya Joy
Cureus, 2021
View PDFchevron_right
Prior use of carbapenems may be a significant risk factor for extended-spectrum b-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia
Alex Martos
2006
View PDFchevron_right
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Joaquin Bermejo
Antimicrobial Agents and Chemotherapy, 2016
View PDFchevron_right
Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
Sveva Di Franco
Antibiotics
View PDFchevron_right
β-Lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: a multinational, pre-registered cohort study
Nuria Prim
Antimicrobial Agents and Chemotherapy, 2016
View PDFchevron_right
Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison
Sarah Wordsworth, Steve Edwards
Current Medical Research and Opinion, 2009
View PDFchevron_right
Streamlining to Oral β-Lactam Versus Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
Karen Fong
Infectious Diseases in Clinical Practice, 2019
View PDFchevron_right
Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study
Marcelle Alves
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program
Miguel Sánchez García
Antimicrobial agents and chemotherapy, 2016
View PDFchevron_right
Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study
Erwann Cariou
Annals of Intensive Care, 2023
View PDFchevron_right
A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome
Anna Levin
BMC Infectious Diseases, 2016
View PDFchevron_right
Impact of Carbapenem Resistance and Receipt of Active Antimicrobial Therapy on Clinical Outcomes of Acinetobacter baumannii Bloodstream Infections
Michael Postelnick, Marc Scheetz
Antimicrobial Agents and Chemotherapy, 2011
View PDFchevron_right
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
ashraf hassanien
BMC Infectious Diseases, 2019
View PDFchevron_right
Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Takahiko Fukuchi
View PDFchevron_right
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Dorothy Mccoy
Antimicrobial Agents and Chemotherapy, 2017
View PDFchevron_right
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Patrick Harris, Emma McBryde
Trials, 2015
View PDFchevron_right
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial
Paul Griffin
JAMA, 2018
View PDFchevron_right
Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase–Producing Bacteria?
Robert Bonomo
Clinical Infectious Diseases, 2011
View PDFchevron_right
The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies
Margherita Chiamenti
BMC Infectious Diseases, 2021
View PDFchevron_right